Building on compelling preclinical efficacy, efforts in translating BRD4 probe compounds into clinical drug candidates have resulted in a number of ongoing clinical programs, testing BRD4 inhibition in a wide range of solid and hematologic malignancies including Nut Midline Carcinoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Diffuse Large B-cell Lymphoma, and Glioblastoma Multiforme [13–21]. This evidence concerns the gene BRD4 and glioblastoma.